UPDATE OF HEART FAILURE MANAGEMENT

Saturday, March 7, 2026

9:35 AM - 10:35 AM EST

Location: Georgetown

Moderator(s)

Jonathan Grinstein, MD

Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation Physician
University of Chicago
MedStar Washington Hospital Center
Bethesda, MD, United States

Disclosure information not submitted.
Richa Gupta, MD

Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiology
MedStar Health

Disclosure information not submitted.
PL

Phillip H. Lam, MD

Advanced Heart Failure Cardiologist
MedStar Health

Disclosure information not submitted.
Ryan J. Tedford, MD

Chief, Heart Failure; Peter C. Gazes Chair in Heart Failure
Medical University of South Carolina, South Carolina, United States

Disclosure(s): 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

Ryan Tedford, MD: 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)